
SeaStar Medical Holding Corp
93
Recent developments highlight SeaStar Medical’s Q3 2026 financial results reporting wider losses due to increased R&D expenses, ongoing enrollment in pivotal clinical trials, FDA confirmation of meeting post-approval study requirements for QUELIMMUNE, and positive pediatric survival data.
- SeaStar Medical reported third quarter 2026 financial results and provided business updates, including ongoing clinical trial progress and regulatory milestones [N1].
- The company posted a wider loss in Q3 2026 attributed to higher research and development expenses [N2].
- The Q3 2026 earnings call discussed clinical trial enrollment, regulatory interactions, and commercial adoption efforts [N3].
- SeaStar Medical confirmed FDA determination that it meets post-approval study requirements for QUELIMMUNE, supporting continued commercialization [N1].
- Positive survival data from pediatric patients treated with QUELIMMUNE were reported, reinforcing clinical benefits [N1].
- The company received FDA Breakthrough Device Designation for SCD therapy in adult sepsis indication, advancing regulatory pathway [N1].
- SeaStar Medical raised capital through warrant exercises to support ongoing development and commercialization activities [N1].
SeaStar Medical Holding Corp develops and commercializes the Selective Cytopheretic Device (SCD), an extracorporeal membrane therapy targeting activated neutrophils and monocytes to reduce destructive hyperinflammation in critically ill patients. The company’s first FDA-approved product, QUELIMMUNE, is indicated for pediatric patients with acute kidney injury (AKI) due to sepsis requiring kidney replacement therapy. SeaStar is conducting pivotal clinical trials for adult AKI patients and exploring additional indications including cardiorenal syndrome and systemic inflammatory response in cardiac surgery. The SCD therapy integrates with existing continuous renal replacement therapy (CRRT) systems using regional citrate anticoagulation to modulate immune cells without causing immunosuppression. The company holds multiple FDA Breakthrough Device Designations and a robust patent portfolio supporting its technology platform.
SeaStar Medical Holding Corp is a commercial-stage healthcare company specializing in its Selective Cytopheretic Device (SCD) therapy, designed to modulate hyperinflammation in critically ill patients with organ failure. The company markets QUELIMMUNE, an FDA-approved pediatric SCD therapy for acute kidney injury due to sepsis, with ongoing clinical trials for adult indications. As of September 30, 2026, SeaStar reported current assets of $4.967 million, current liabilities of $4.841 million, and a net loss of $4.529 million for the quarter, with a current ratio of 1.03. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
SeaStar Medical’s SCD therapy addresses a significant unmet medical need in managing hyperinflammation and organ failure in critically ill patients. Positive clinical data demonstrating mortality reduction and improved organ function in pediatric and adult patients support the therapy’s potential impact. The company’s ongoing pivotal trial in adults and multiple FDA Breakthrough Device Designations may facilitate regulatory approvals and broaden indications. Adoption of QUELIMMUNE in pediatric hospitals and real-world safety data from the SAVE registry enhance commercial prospects. The scalable platform and broad applicability across acute and chronic inflammatory diseases present opportunities for market expansion.
SeaStar Medical faces risks including the inherent uncertainties of clinical trial outcomes, regulatory approvals, and market adoption of its SCD therapy beyond pediatric indications. The company’s financial position shows limited cash reserves and ongoing net losses, reflecting the need for continued capital to fund R&D and commercialization. Adoption of QUELIMMUNE requires institutional review board approvals and hospital activations, which may slow commercial uptake. Competition from alternative therapies and potential challenges in demonstrating long-term efficacy and safety could impact business prospects.
SeaStar Medical’s moat derives from its proprietary SCD technology platform, which is protected by a portfolio of 46 patents and exclusive licensing agreements with the University of Michigan. The SCD therapy’s unique mechanism of selectively binding and deactivating activated neutrophils and monocytes in a low calcium environment differentiates it from existing immunosuppressive or cytokine-targeting therapies. FDA approvals, including a Humanitarian Device Exemption for pediatric use and multiple Breakthrough Device Designations for adult indications, provide regulatory advantages. The therapy’s integration with widely used CRRT systems and the company’s clinical trial progress further support barriers to entry.
• Clinical and Regulatory Risk: The success of SeaStar Medical depends on positive outcomes from ongoing and future clinical trials, including the pivotal NEUTRALIZE-AKI trial in adults, and obtaining necessary regulatory approvals for expanded indications.
• Financial Risk: The company reported a net loss of $4.529 million for the quarter ended September 30, 2026, with limited cash and equivalents, indicating reliance on additional financing to support operations and development.
• Commercial Adoption Risk: Adoption of QUELIMMUNE requires hospital institutional review board approvals and participation in post-approval registries, which may delay or limit market penetration.
• Competitive and Market Risk: Alternative therapies targeting hyperinflammation and organ failure exist, and SeaStar Medical must demonstrate differentiated clinical benefits to gain market share.
Business trends: Continued clinical trial enrollment and regulatory progress for SCD therapy in pediatric and adult indications, with expanding real-world data collection.
Execution milestones: Completion of pivotal NEUTRALIZE-AKI trial enrollment, FDA regulatory submissions, and expanded commercial adoption of QUELIMMUNE.
Key risks: Clinical trial and regulatory uncertainties, financial constraints, and challenges in hospital adoption and market competition.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- SeaStar Medical Holding Corp is a commercial-stage healthcare company focused on treatments for critically ill patients with organ failure and hyperinflammation [S1].
- The company’s core product is the Selective Cytopheretic Device (SCD), designed to neutralize overactive immune cells and stop cytokine storms causing hyperinflammation [S1].
- SCD therapy has FDA approval under a Humanitarian Device Exemption (HDE) for pediatric patients with acute kidney injury (AKI) due to sepsis requiring kidney replacement therapy; the product is marketed as QUELIMMUNE [S1].
- QUELIMMUNE shipments began in July 2024, targeting pediatric medical facilities with a post-approval patient surveillance registry (SAVE) to track safety and performance [S1].
- As of December 31, 2025, 10 active commercial hospital customers had adopted QUELIMMUNE and completed registry processes, with plans for additional activations in 2026 [S1].
- Early real-world data from 21 pediatric patients in the SAVE registry showed no device-related safety events, 76% survival at 60 days, and 71% at 90 days, supporting a 50% reduction in mortality compared to historical data [S1].
- The FDA approved reducing the SAVE registry enrollment from 300 to 50 patients based on safety data; the 50th patient was enrolled on March 4, 2026 [S1].
- SeaStar is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult patients with AKI requiring continuous renal replacement therapy (CRRT) to assess safety and efficacy of SCD therapy [S1].
- As of March 13, 2026, 178 patients were enrolled in the NEUTRALIZE-AKI trial, which plans to enroll 339 patients total with an interim analysis after 100 subjects [S1].
- The company has received six FDA Breakthrough Device Designations (BDD) covering multiple adult indications including AKI, cardiorenal syndrome, hepatorenal syndrome, end-stage renal disease, and systemic inflammatory response during cardiac surgery [S1].
- SCD therapy is an extracorporeal membrane device integrated into existing CRRT systems using regional citrate anticoagulation (RCA) to modulate activated neutrophils and monocytes, reducing hyperinflammation without immunosuppression [S1].
- The mechanism involves selective binding and deactivation of highly activated neutrophils and monocytes in a low ionized calcium environment, followed by release back into circulation (catch-and-release) [S1].
- Clinical and preclinical studies over 15 years show SCD therapy reduces mortality by 50% in over 150 pediatric and adult patients with AKI on CRRT, with survivors not requiring dialysis at 60 days [S1].
- The company holds a patent portfolio of 46 patents and 1 pending application, including exclusive licenses from the University of Michigan for commercialization in human therapeutic indications [S1].
- Financial snapshot as of September 30, 2026: current assets $4.967 million, current liabilities $4.841 million, cash and equivalents $51,567, net loss $4.529 million, basic EPS -$1.03; current ratio 1.03, cash ratio 0.01 [S2].
- Recent news includes Q3 2026 financial results reporting wider losses due to higher R&D expenses, ongoing clinical trial enrollment, FDA confirmation of meeting post-approval study requirements, and positive pediatric survival data with QUELIMMUNE [N1][N2][N3].
- SeaStar Medical’s SCD therapy has received FDA Breakthrough Device Designation for adult sepsis indication, and the company has raised capital through warrant exercises [N1][N2][N3].
Generated 2026-11-15
- N3
- N4
- N7
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates | https://www.nasdaq.com/articles/seastar-medical-reports-third-quarter-2026-financial-results-and-provides-business-updates
- N2 | 2026-11-12 | www.nasdaq.com | SeaStar Medical Posts Wider Loss In Q3 On Higher R&D Expenses | https://www.nasdaq.com/articles/seastar-medical-posts-wider-loss-q3-higher-rd-expenses
- N3 | 2026-11-12 | www.nasdaq.com | SeaStar Medical (ICU) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/seastar-medical-icu-q3-2026-earnings-call-transcript
- N4 | 2026-08-13 | www.nasdaq.com | SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/seastar-medical-icu-q2-2026-earnings-call-transcript
- N5 | 2026-08-10 | www.nasdaq.com | SeaStar Medical Gains 13% Ahead Of Q2 Results As Critical Care Pipeline Advances | https://www.nasdaq.com/articles/seastar-medical-gains-13-ahead-q2-results-critical-care-pipeline-advances
- N6 | 2026-07-02 | www.nasdaq.com | Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-canf-climbs-rgnt-gears-europe-launch-rnaz-eltx-watch
- N7 | 2026-05-13 | www.nasdaq.com | SeaStar Medical (ICU) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/seastar-medical-icu-q1-2026-earnings-transcript
- N8 | 2026-03-26 | www.nasdaq.com | SeaStar Medical Jumps On Q4 Revenue Growth; Exceeds 50% Enrolment In NEUTRALIZE-AKI Pivotal Trial | https://www.nasdaq.com/articles/seastar-medical-jumps-q4-revenue-growth-exceeds-50-enrolment-neutralize-aki-pivotal-trial
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


